| Gene symbol | CD19 | Synonyms | B4, CVID3 | Type of gene | protein-coding |
| Chromosome | 16 | Map location | 16p11.2 | dbXrefs | |
| Description | CD19 molecule | ||||
| Gene symbol | MS4A1 | Synonyms | B1, Bp35, CD20, CVID5, FMC7, LEU-16, S7 | Type of gene | protein-coding |
| Chromosome | 11 | Map location | 11q12.2 | dbXrefs | |
| Description | membrane spanning 4-domains A1 | ||||
| GTO ID | GTC2458 |
| Trial ID | NCT04553393 |
| Disease | Refractory or Relapsed Aggressive R/R B-NHL with Huge Tumor Burden |
| Altered gene | CD19|CD20 |
| Therapeutic/Target gene | Target gene |
| Therapy | CAR-T cell |
| Treatment | CD19/CD20 CAR-T cells |
| Co-treatment | chidamidEdecitabine |
| Phase | Phase1|Phase2 |
| Recruitment status | Unknown |
| Title | Decitabine-primed Tandem CD19/CD20 CAR T Cells Plus Epigenetic Agents in Aggressive r/r B-NHL With Huge Tumor Burden |
| Year | 2020 |
| Country | China |
| Company sponsor | Chinese PLA General Hospital |
| Other ID(s) | CHN-PLAGH-BT-060 |
| Cohort 1 | |||||||
|
|||||||